{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:52:54Z","timestamp":1790236374972,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Grants-in-Aid for Young Scientists (B)","award":["24791329"],"award-info":[{"award-number":["24791329"]}]},{"name":"Grants-in-Aid for Young Scientists (B)","award":["15K19810"],"award-info":[{"award-number":["15K19810"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","nucmedbio.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.nucmedbio.2017.07.002","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T19:47:04Z","timestamp":1499888824000},"page":"18-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["111 In-DTPA- d -Phe \u22121 -Asp 0 - d -Phe 1 -octreotide exhibits higher tumor accumulation and lower renal radioactivity than 111 In-DTPA- d -Phe 1 -octreotide"],"prefix":"10.1016","volume":"54","author":[{"given":"Nobuhiro","family":"Oshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Kitaura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songji","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Arano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Ohkura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0005","first-page":"1","article-title":"Somatostatin and its analogs","volume":"16","author":"Sun","year":"2015","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0010","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with sutype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1385\/MO:20:1:59","article-title":"Expression of somatostatin receptor subtype 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors","volume":"20","author":"Fj\u00e4llskog","year":"2003","journal-title":"Med Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.nucmedbio.2017.07.002_bb0020","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/s00428-007-0443-2","article-title":"Peptide receptor expression in GEP-NET","volume":"451","author":"Reubi","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/gut.40.2.267","article-title":"Expression of peptide receptors in human endocrine tumors of the pancreas","volume":"40","author":"Tang","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0030","series-title":"Book chapter 2","article-title":"Radiolabeled somatostatin analogues for use in molecular imaging, somatostain: synthesis, mechanism-of-action and physiological effect, ISBN: 978-1-62417-419-3","author":"Blom","year":"2012"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0035","doi-asserted-by":"crossref","first-page":"42S","DOI":"10.2967\/jnumed.110.085753","article-title":"Radiopeptide imaging and therapy in Europe","volume":"52","author":"Ambrosini","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0040","doi-asserted-by":"crossref","first-page":"56S","DOI":"10.2967\/jnumed.110.085746","article-title":"Radiopeptide imaging and therapy in the United States","volume":"52","author":"Graham","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0045","doi-asserted-by":"crossref","first-page":"448","DOI":"10.7150\/thno.3931","article-title":"Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs)","volume":"2","author":"\u00d6berg","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0001-2998(95)80014-X","article-title":"Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (octreoscan)","volume":"3","author":"Olsen","year":"1995","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0055","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/0024-3205(91)90053-E","article-title":"In vivo application of [111In-DTPA-d-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats","volume":"49","author":"Bakker","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0060","first-page":"652","article-title":"Somatostatin receptor scintigraphy with indium-111-DTPA-d-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0065","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0070","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdp372","article-title":"Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study","volume":"21","author":"Cwikla","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","article-title":"Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine","volume":"30","author":"Rolleman","year":"2003","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0080","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/bjc.1993.266","article-title":"Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue","volume":"67","author":"Hammond","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0085","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0969-8051(01)00241-4","article-title":"Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides","volume":"28","author":"Akizawa","year":"2001","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0090","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1248\/bpb.30.2226","article-title":"Effect of carboxyl-group of d-glutamic acid or gamma-carboxy-d-glutamic acid as N-terminal amino acid of 111In-diethylenetriaminepentaacetic acid-octreotide on accumulation of radioactivity in kidney","volume":"30","author":"Akizawa","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1248\/bpb.27.271","article-title":"Effect of carboxylation of N-terminal phenylalanine of 111In-DTPA (diethylenetriaminepentaacetic acid)-octreotide on accumulation of radioactivity in kidney","volume":"27","author":"Akizawa","year":"2004","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0100","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.bmc.2013.12.063","article-title":"Design, synthesis and biological evaluation of negatively charged 111In-DTPA-octreotide derivatives","volume":"22","author":"Oshima","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.nucmedbio.2017.01.006","article-title":"Redesign of negatively charged 111In-DTPA-octreotide derivative to reduce renal radioactivity","volume":"48","author":"Oshima","year":"2017","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0110","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1021\/jm950949+","article-title":"Reassessment of diethylenetriaminepentaacetic acid (DTPA) as a chelating agent for indium-111 labeling of polypeptides using a newly synthesized monoreactive DTPA derivative","volume":"39","author":"Arano","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0115","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1021\/bc970023b","article-title":"Conventional and high-yield synthesis of DTPA-conjugated peptides: application of a monoreactive DTPA to DTPA-d-Phe1-octreotide synthesis","volume":"8","author":"Arano","year":"1997","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0120","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/bc049972c","article-title":"Evaluation of cleavable (Tyr3)-octreotate derivatives for longer intracellular probe residence","volume":"15","author":"Whetstone","year":"2004","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0125","first-page":"1016","article-title":"Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides","volume":"37","author":"Vallabhajosula","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0130","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00259-002-0782-9","article-title":"[99mTc]Demotate, a new 99mTc-based[Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumors: synthesis and preclinical results","volume":"29","author":"Maina","year":"2002","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0135","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1021\/jm100246m","article-title":"Synthesis of DOTA-conjugated multimeric [Tyr3]octreotide peptides via a combination of Cu(I)-catalyzed \u201cclick\u201d cycloaddition and thio acid\/sulfonyl azide \u201csulfo-click\u201d amidation and their in vivo evaluation","volume":"53","author":"Yim","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0140","first-page":"892","article-title":"Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs","volume":"45","author":"Poethko","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0145","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/bc9702258","article-title":"Renal metabolism of 111In-DTPA-d-Phe1-octreotide in vivo","volume":"9","author":"Akizawa","year":"1998","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.apradiso.2010.09.005","article-title":"Radiopeptide internalization and externalization assays: Cell viability and radioligand integrity","volume":"69","author":"Naqvi","year":"2011","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0155","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1021\/jm060317v","article-title":"Validation of a novel CHX-A\" derivative suitable for peptide conjugation: Small animal PET\/CT imaging using Yttrium-86-CHX-A\"-octreotide","volume":"49","author":"Clifford","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2017.07.002_bb0160","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/bc970158h","article-title":"Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-d-Phe1-octreotide","volume":"9","author":"Bass","year":"1998","journal-title":"Bioconjug Chem"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117301373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805117301373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T07:51:51Z","timestamp":1535615511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805117301373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":32,"alternative-id":["S0969805117301373"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.07.002","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"111In-DTPA-d-Phe\u22121-Asp0-d-Phe1-octreotide exhibits higher tumor accumulation and lower renal radioactivity than 111In-DTPA-d-Phe1-octreotide","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}